Avenue Therapeutics Valuation
| ATXI Stock | USD 1.10 0.15 12.00% |
Today, the firm appears to be undervalued. Avenue Therapeutics shows a prevailing Real Value of $2.81 per share. The current price of the firm is $1.1. Our model approximates the value of Avenue Therapeutics from analyzing the firm fundamentals such as return on equity of -5.35, and Current Valuation of (358.22 K) as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Avenue Therapeutics' valuation include:
Price Book 0.8578 | Enterprise Value | Enterprise Value Ebitda (0.42) | Forward PE 17.9856 | Trailing PE 0.0444 |
Undervalued
Today
Please note that Avenue Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Avenue Therapeutics is based on 3 months time horizon. Increasing Avenue Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Avenue Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Avenue Stock. However, Avenue Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.1 | Real 2.81 | Target 8.0 | Hype 1.16 | Naive 1.06 |
The intrinsic value of Avenue Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Avenue Therapeutics' stock price.
Estimating the potential upside or downside of Avenue Therapeutics helps investors to forecast how Avenue stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Avenue Therapeutics more accurately as focusing exclusively on Avenue Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Avenue Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Avenue Therapeutics Cash |
|
Avenue Valuation Trend
Avenue Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Avenue Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Avenue Therapeutics Total Value Analysis
Avenue Therapeutics is presently anticipated to have valuation of (358.22 K) with market capitalization of 2.26 M, debt of 1.2 M, and cash on hands of 890 K. The negative valuation of Avenue Therapeutics may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Avenue Therapeutics fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(358.22 K) | 2.26 M | 1.2 M | 890 K |
Avenue Therapeutics Asset Utilization
One of the ways to look at asset utilization of Avenue is to check how much profit was generated for every dollar of assets it reports. Avenue Therapeutics shows a negative utilization of assets of -4.72 percent, losing $0.0472 for each dollar of assets held by the firm. Unsuccessful asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Avenue Therapeutics shows how unproductive it operates for each dollar spent on its assets.Avenue Therapeutics Ownership Allocation
Avenue Therapeutics retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares.Avenue Therapeutics Profitability Analysis
Net Loss for the year was (10.38 M) with profit before overhead, payroll, taxes, and interest of 0.About Avenue Therapeutics Valuation
An absolute valuation paradigm, as applied to Avenue Stock, attempts to find the value of Avenue Therapeutics based on its fundamental and basic technical indicators. By analyzing Avenue Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Avenue Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Avenue Therapeutics. We calculate exposure to Avenue Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Avenue Therapeutics's related companies.Avenue Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 141.2 K | |
| Quarterly Earnings Growth Y O Y | -0.763 | |
| Forward Price Earnings | 17.9856 | |
| Shares Float | 1.4 M |
Avenue Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Avenue Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Avenue we look at many different elements of the entity such as Avenue's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Avenue Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Avenue Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Avenue Therapeutics' worth.Complementary Tools for Avenue Stock analysis
When running Avenue Therapeutics' price analysis, check to measure Avenue Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avenue Therapeutics is operating at the current time. Most of Avenue Therapeutics' value examination focuses on studying past and present price action to predict the probability of Avenue Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avenue Therapeutics' price. Additionally, you may evaluate how the addition of Avenue Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |